Japan Australia Gallium Associates

Japan Australia Gallium Associates (JAGA) is a biotechnology company dedicated to the development and commercialization of gallium-based therapeutic compounds. The company's lead candidate, Gallium maltolate, is a proprietary, orally bioavailable coordination complex designed to treat various cancers, inflammatory conditions, and infectious diseases. By acting as a mimetic of ferric iron, Gallium maltolate disrupts iron-dependent metabolic processes, specifically inhibiting the enzyme ribonucleotide reductase to prevent DNA synthesis in rapidly dividing cells. JAGA manages an extensive portfolio of intellectual property related to the medical applications of gallium and has advanced its lead compound into Phase 1 and Phase 2 clinical trials. The company primarily operates through a model of collaborative research and licensing to bring its metal-based therapies to market.